The OTCPharm Pro plant to open in Kaliningrad will manufacture a wide range of pharmaceuticals the Russian market needs, including antibiotics, antivirals, immunomodulators, analgesics, nootropics and mucolytics.
The Biokhimik facility in Saransk will launch the production of 130 pharmaceutical substances, including medications to treat oncological and cardiovascular diseases and HIV, as well as antibiotics, anti-inflammatory drugs and myorelaxants.
The second stage of the Pharmasyntez-Nord plant in St Petersburg will increase the production of biotechnological pharmaceutical substances and drugs for oncological and autoimmune diseases in humans, as well as genetically engineered insulins and the Sputnik Light Covid-19 vaccine.